Trial Profile
An Open Phase I Repeated Dose Escalation Study of BI 2536 BS Administered Intravenously in Patients With Advanced Solid Tumours With Repeated Administration in Patients With Clinical Benefit
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 11 Aug 2014
Price :
$35
*
At a glance
- Drugs BI 2536 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Boehringer Ingelheim
- 11 Aug 2014 New trial record